Although a clinical setback last year continues to loom in the background, AbbVie’s $8.7 billion bet on Cerevel Therapeutics ...

The commercial environment facing today's life sciences sales teams looks very different from the one many organizations were ...

From its original U.S. home base in Deerfield, Illinois, Lundbeck now plans to relocate its local headquarters to Greater ...

Bristol Myers Squibb plans another major round of job cuts in New Jersey, bringing the number of total layoffs the company ...

Merck & Co. has scored an FDA approval for its blockbuster-to-be Welireg to move into second-line treatment of kidney cancer, ...

In just over a month, the FDA has cleared not one, but two treatments for fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic condition that causes soft tissues to turn to bone. | Mirum ...

Eli Lilly and InnoCare Pharma inked a multi-target deal potentially worth $3.35 billion. The FDA has doled out the first approval for a novel cancer drug from a Korean company. | Eli Lilly and ...

Novo CEO Mike Doustdar—tapped to breathe new life into the Danish drugmaker last year after losing GLP-1 marketing ground to ...

A U.K. watchdog has scolded Eli Lilly over a press release the drugmaker sent to the BBC, arguing that its use of ...

GSK showed a “totally unacceptable” lack of transparency in its interactions wi | GSK showed a “totally unacceptable” lack of transparency in its interactions with the PMCPA, the U.K. self-regulatory ...

"These Phase 3 results build on the established efficacy of Caplyta in bipolar depression and represent an important step in evaluating its potential to address both depressive and acute manic ...

In their lawsuit, BMS and Ono accuse Amgen of aiming to market its biosimilar ahead of the expiration of key U.S. patents ...